Form 4: Tarsus Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units

Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, received stock options for 42,500 shares and 28,702 restricted stock units (RSUs) on March 7, 2024.

Summary

• Bryan Wahl, the General Counsel of Tarsus Pharmaceuticals, was granted stock options and restricted stock units.
• On March 7, 2024, Wahl received options to purchase 42,500 shares of Tarsus Pharmaceuticals' common stock at an exercise price of $35.50.
• These options vest over a four-year period, with 25% vesting on March 7, 2025, and the remainder vesting monthly over the subsequent three years, contingent upon continuous service.
• Wahl also received 28,702 restricted stock units (RSUs), each representing the right to receive one share of Tarsus Pharmaceuticals' common stock.
• These RSUs vest in four equal installments of 25% on March 15th of each of 2025, 2026, 2027, and 2028, also subject to continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The granting of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and retention.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Granting stock options and RSUs is a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives. These grants align management's interests with those of shareholders by rewarding them for increasing the company's value.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in publicly traded pharmaceutical companies.
• Companies like Alnylam Pharmaceuticals, BioMarin Pharmaceutical, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans to incentivize their leadership teams.
• The vesting schedules described are typical, with multi-year vesting periods designed to promote long-term commitment.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs positively as it incentivizes management to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates